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ORIGINAL ARTICLE
The effect of obesity on electrocardiographic detection
of hypertensive left ventricular hypertrophy: recalibration
against cardiac magnetic resonance
JCL Rodrigues1,2, B McIntyre3, AG Dastidar1, SM Lyen1,4, LE Ratcliffe5, AE Burchell5, EC Hart2,5, C Bucciarelli-Ducci1, MCK Hamilton1,4,
JFR Paton2,5, AK Nightingale2,5 and NE Manghat1,4
Electrocardiograph (ECG) criteria for left ventricular hypertrophy (LVH) are a widely used clinical tool. We recalibrated six ECG
criteria for LVH against gold-standard cardiac magnetic resonance (CMR) and assessed the impact of obesity. One hundred and ﬁfty
consecutive tertiary hypertension clinic referrals for CMR (1.5 T) were reviewed. Patients with cardiac pathology potentially
confounding hypertensive LVH were excluded (n= 22). The ﬁnal sample size was 128 (age: 51.0 ± 15.2 years, 48% male). LVH was
deﬁned by CMR. From a 12-lead ECG, Sokolow–Lyon voltage and product, Cornell voltage and product, Gubner–Ungerleidger
voltage and Romhilt–Estes score were evaluated, blinded to the CMR. ECG diagnostic performance was calculated. LVH by CMR was
present in 37% and obesity in 51%. Obesity signiﬁcantly reduced ECG sensitivity, because of signiﬁcant attenuation in mean ECG
values for Cornell voltage (22.2 ± 5.7 vs 26.4 ± 9.4 mm, Po0.05), Cornell product (2540 ± 942 vs 3023 ± 1185mm • ms, Po0.05) and
for Gubner–Ungerleider voltage (18.2 ± 7.1 vs 23.3 ± 1.2 mm, Po0.05). Obesity also signiﬁcantly reduced ECG speciﬁcity, because of
signiﬁcantly higher prevalence of LV remodeling (no LVH but increased mass-to-volume ratio) in obese subjects without LVH (36%
vs 16%, Po0.05), which correlated with higher mean ECG LVH criteria values. Obesity-speciﬁc partition values were generated at
ﬁxed 95% speciﬁcity; Cornell voltage had highest sensitivity in non-obese (56%) and Sokolow–Lyon product in obese patients
(24%). Obesity signiﬁcantly lowers ECG sensitivity at detecting LVH, by attenuating ECG LVH values, and lowers ECG speciﬁcity
through changes associated with LV remodeling. Our obesity-speciﬁc ECG partition values could improve the diagnostic
performance in obese patients with hypertension.
Journal of Human Hypertension advance online publication, 4 June 2015; doi:10.1038/jhh.2015.58
INTRODUCTION
In patients with arterial hypertension, left ventricular hypertrophy
(LVH) is a powerful independent predictor for sudden cardiac
death,1 ventricular arrhythmias,2 myocardial ischemia,3 coronary
heart disease4 and heart failure,5 as well as ischemic stroke.6
The 2013 European Society of Hypertension/European Society
of Cardiology guidelines for the management of arterial
hypertension recommend that a 12-lead electrocardiograph
(ECG) be performed for all patients with arterial hypertension,
partly to detect the presence of LVH.7 The ECG criteria for
LVH have previously been validated against M-mode and
two-dimensional echocardiography.8–11 However, cardiac
magnetic resonance (CMR) assessment of left ventricular mass
(LVM) has been demonstrated to be more accurate and more
reproducible than both M-mode and two-dimensional
echocardiography.12–14 Consequently, CMR is the current non-
invasive gold-standard investigation for assessing LVM.15 Yet,
there is a paucity of studies comparing the diagnostic perfor-
mance of the ECG at detecting LVH relative to CMR gold-standard.
Furthermore, previous CMR studies (i) have not been in the
context of hypertension,16 (ii) have been in unselected CMR
referrals for all indications17 or (iii) have been in hypertensive
subjects but using older turbogradient echo CMR sequences,18
which have been demonstrated to overestimate LV mass by
13 gm−2 in comparison with the more accurate steady-state free
precession (SSFP) sequence.19 It is, therefore, apparent that the
ECG criteria for LVH in hypertension have potentially been
validated, to date, against variable reference standards. In spite
of this, the ECG is invariably the ﬁrst-line diagnostic tool for the
assessment for LVH in hypertensive patients, and treatment
decisions may be made on its results. Therefore, understanding
the diagnostic performance of the ECG at detecting LVH relative
to gold-standard is of paramount importance.
Arterial hypertension and obesity commonly coexist. The latter
has been associated with increased LVM and increased prevalence
of LVH independent of hypertension.20 However, previous
echocardiographic studies into the impact of obesity on the
diagnostic performance of the ECG at detecting LVH have
demonstrated conﬂicting results.21–24
Consequently, the aim of our study was to evaluate the
Sokolow–Lyon voltage, Sokolow–Lyon product, Cornell voltage,
Cornell product, Gubner–Ungerleider voltage and Romhilt–Estes
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ECG criteria for LVH in a cohort of tertiary hypertensive clinic
patients, with high prevalence of LVH, relative to SSFP CMR
measurements of LVM. We also aimed to investigate the effect of
obesity and LV remodeling on the ECG criteria for LVH and
generate new obesity-speciﬁc partition values, by recalibrating the
criteria against the current noninvasive gold-standard technique
to measure LVM.
MATERIALS AND METHODS
Study population
This was a prospective study of consecutive eligible patients with arterial
hypertension referred for CMR from a tertiary hypertension clinic serving
the South West of England. Study participants underwent CMR as part of
their clinical hypertension work-up between January 2011 and December
2014. In our institution, CMR is used as part of the investigation for
secondary causes of hypertension and to quantify hypertensive end-organ
damage. To assess hypertensive LVH, exclusion criteria consisted of all
concomitant cardiac pathology that may confound the hypertrophic
response, including moderate–severe valvular heart disease and clinical or
CMR evidence of prior myocardial infarction or other cardiomyopathy. In
particular, hypertrophic cardiomyopathy was excluded on the basis of
clinical and family history, as well as CMR appearance. There were no high-
performing athletes in the cohort, mitigating against the presence of
physiological hypertrophy among the subjects.
Baseline demographics and clinical characteristics were recorded.
Obesity was deﬁned as a body mass index (BMI) 430 kgm−2. Systolic
(SBP) and diastolic (DBP) blood pressure values were the mean ofﬁce blood
pressure readings taken at the time of the ECG of repeat readings from
both arms, where available, after the patient had been sitting for 5 min
with an appropriately sized cuff.
The local research ethics committee conﬁrmed that the study
conformed to the governance arrangements for research ethics commit-
tees. The study was conducted with the patient's written consent.
Electrocardiograph
A 12-lead standard ECG (scale: 10 mm=1mV; speed: 25 mm s− 1) was
acquired in the supine position during quiet respiration and analyzed by a
clinician blinded to the CMR data. Subjects with complete bundle branch
block were excluded. The six ECG criteria evaluated for LVH (Table 1) were
as follows: Sokolow–Lyon voltage,25 Sokolow–Lyon product,10,26 Cornell
voltage,8 Cornell voltage product,10,26 Gubner–Ungerleider voltage27 and
Romhilt–Estes score.28
CMR protocol and analysis
CMR was performed at 1.5 T (Avanto, Siemens, Erlangen, Germany). The
CMR protocol included short-axis SSFP cines with whole LV coverage
(8mm slice thickness, no slice gap, temporal resolution 38.1 ms, echo time
1.07ms, in-plane pixel size 1.5 × 0.8 mm2) for the assessment of LVM. In
addition, late gadolinium myocardial enhancement was routinely
performed using an inversion-recovery fast gradient echo sequence and
a phase-sensitive inversion-recovery sequence performed in two-phase-
encoding directions ~ 10–15min after intravenous administration of
0.1 mmol kg− 1 gadobutrol (Gadovist; Bayer Pharma AG, Berlin, Germany).
Tailored inversion times were used in each patient to achieve myocardial
nulling. Subjects with subendocardial late gadolinium myocardial
enhancement consistent with previous myocardial infarction were
excluded. Routine renovascular assessment was also part of routine
hypertension work-up, consisting of Time-resolved angiography With
Interleaved Stochastic Trajectories (TWIST) contrast-enhanced magnetic
resonance angiography, which creates multiphase, multiplanar images of
the abdominal vasculature.
The assessment of LVM was performed as described previously, which
also used thresholding software analysis.29 Brieﬂy, endocardial contours
were deﬁned at end-diastole and end-systole on the LV short-axis stack
using blood pool/endocardial border threshold detection software (cmr42;
Circle Cardiovascular Imaging Inc., Calgary, AB, Canada), which has been
previously validated.30 Epicardial contours were deﬁned manually at end-
diastole. The LVM was estimated by multiplying the total myocardial
volume, including papillary muscles and LV trabeculations (equivalent to
LV dry weight), by 1.05 gml− 1, which is the speciﬁc gravity of myocardium,
as described previously.29 The LVM and end-diastolic and end-systolic
volumes were indexed to body surface area, calculated using the Mosteller
formula. LVH was deﬁned as indexed LVM495th percentile of established
CMR reference ranges indexed to body surface area (men: 89–93 gm− 2
and women: 77–78 gm−2 depending on age).29 LV remodeling was
deﬁned as a ventricle with normal indexed LVM but elevated LV
mass/volume ratio (M/V).16 An increased M/V was deﬁned as 495th
gender-speciﬁc percentile (men:41.12 gml− 1 and women:41.14 g ml− 1)
from healthy volunteers, as described previously.16 Asymmetric wall
thickness was deﬁned as a regional wall thickness ⩾ 13mm also 41.5-
fold the thickness of the contralateral myocardial segment.31 The CMR
analysis was performed by an experienced CMR reader blinded to the ECG
data. All CMR readings were repeated twice and the mean value used for
analysis. The intraobserver percentage variability in repeat measurements
was 3.4 ± 2.5% and the intraobserver intraclass correlation coefﬁcient (two-
way mixed, absolute agreement, average measures) was 0.991 (95%
conﬁdence interval (CI): 0.987–0.994).
Statistical analysis
Statistical analysis was performed using SPSS version 21 (IBM Corp.,
Armonk, NY, USA). Continuous variables were expressed as mean± s.d. and
normally distributed variables were compared using unpaired Student’s
T-tests or one-way analysis of variance with least signiﬁcant difference post
hoc correction as appropriate. Categorical variables were expressed as
percentages and analyzed using Fisher’s exact or χ2 tests as appropriate.
Sensitivity, speciﬁcity, positive predictive valve (PPV), negative predictive
value (NPV) and accuracy were also calculated. Receiver-operating
Table 1. The ECG criteria for the detection of LVH included in the study
Formula Deﬁnition of LVH
Sokolow–Lyon voltage25 SV1+RV5 or RV6 ⩾ 35mm
Sokolow–Lyon product10,26 (SV1+RV5 or RV6) ×QRS ⩾ 3710mm ⋅ms
Gubner Ungerleider voltage R1+S3 ⩾ 20mm
Cornell voltage8 RaVL+SV3 ⩾ 28mm (men)
⩾ 20mm (women)
Cornell voltage product10,26 (RaVL+SV3) ×QRS (men) ⩾ 2440mm ⋅ms
(RaVL+SV3+0.8 mV) ×QRS (women)
Romhilt–Estes score 1. Amplitude=R or S wave in limb leads ⩾ 20mm
or SV1–2 ⩾ 30mm or RV5–6 ⩾ 30mm 3 points
⩾ 5 points: deﬁnite LVH
⩾ 4 points: probably LVH
2. ST-T segment pattern=
Without digitalis 3 points
With digitalis 1 point
3. Left atrial involvement 3 points
4. Left axis deviation ⩾ 30o 2 points
5. QRS ⩾ 0.09 s 1 point
6. Intrinsicoid deﬂection ⩾ 0.05 s in V5–6 1 point
Abbreviations: ECG, electrocardiograph; LVH, left ventricular hypertrophy. ECG scale: 10mm= 1mV; speed: 25 mm s− 1.
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characteristics (ROC) analysis was carried out to calculate the area under
the curve (AUC) and to compare the diagnostic performance of the various
ECG criteria. Statistical signiﬁcance was set as two-tailed Po0.05.
RESULTS
Demographics
One hundred and ﬁfty consecutive patients referred for CMR were
assessed for eligibility. Twenty-two patients met the exclusion
criteria (Figure 1), resulting in a ﬁnal sample size of 128 (men: 49%;
age: 51.0 ± 15.2 years) (Table 2). All subjects completed the CMR
study. CMR evidence of LVH was present in 37% (n= 47) and
obesity was present in 51% (n= 65) of the cohort. There were no
signiﬁcant differences between non-obese (n= 63) and obese
subjects (n= 65) in age (50.7 ± 16.7 vs 51.3 ± 13.6 years, P= 0.803),
gender (men: 52% vs 46%, P= 0.596), SBP (171.9 ± 30.0 vs
169.6 ± 30.1 mmHg, P= 0.6641), DBP (98.1 ± 16.0 vs 96.9 ± 14.9
mmHg, P= 0.6604) or CMR prevalence of LVH (29% vs 45%,
P= 0.069). The majority (92%) of patients were taking at least one
antihypertensive medication.
Indexed LVM in subjects with positive ECG criteria
Using established partition values, the mean indexed LVM in those
subjects with ECG evidence of LVH was signiﬁcantly higher
compared in those without ECG evidence of LVH for all the ECG
criteria (Sokolow–Lyon voltage: 96.6 ± 28.4 vs 82.7 ± 20.4 gm−2,
Po0.05; Sokolow–Lyon product: 99.8 ± 31.2 vs 82.9 ± 20.3 g m−2,
Po0.05; Cornell voltage: 96.3 ± 28.6 vs 80.2 ± 17.3 g m−2,
Po0.0005; Cornell product: 93.1 ± 27.7 vs 79.6 ± 16.2 g m−2,
Po0.005; Gubner–Ungerleider voltage: 92.4 ± 24.8 vs 80.5 ±
19.3 g m−2, Po0.005; Romhilt–Estes 4p: 97.0 ± 25.5 vs 76.5 ±
14.6 g m−2, Po0.0001; and Romhilt–Estes 5p: 101.8 ± 31.3 vs
80.9 ± 17.7 g m−2, Po0.0001).
Diagnostic performance of the ECG criteria of LVH
Speciﬁcity was higher than sensitivity for all the ECG criteria
investigated (Table 3), using the traditional partition values
described in Table 1. The Sokolow–Lyon product yielded the
highest speciﬁcity (96%), and the highest sensitivity (55%) was
achieved by the Romhilt–Estes 4p criterion. However, the Cornell
voltage criterion performed best on AUC-ROC analysis (0.752, 95th
CI: 0.666–0.809). By obesity subgroup analysis (Table 4), the
sensitivity for obese subjects compared with non-obese subjects
was signiﬁcantly lower for Cornell voltage (34% vs 56%, Po0.05),
Cornell product (48% vs 61%, Po0.05), Gubner–Ungerleider
voltage (41% vs 67%, Po0.05) and Romhilt–Estes 4p score (45%
vs 72%, Po0.05). Similarly, the speciﬁcity was signiﬁcantly lower
for Cornell product (69% vs 83%, Po0.05) and Gubner–
Ungerleider voltage (61% vs 82%, Po0.05) in the presence of
obesity. The ROC-AUC analysis was inferior for obese subjects
relative to non-obese subjects for Cornell voltage, Cornell product
and Gubner–Ungerleider voltage criteria.
Obesity subgroup analysis of the ECG criteria for LVH
The mean values for each ECG criterion were calculated for
individuals with CMR evidence of LVH and those without CMR
evidence of LVH, by obesity subgroup (Table 5). In the presence
of LVH by CMR, the mean values for Cornell voltage (26.4 ± 9.4
vs 22.2 ± 5.7 mm, Po0.05), Cornell product (3023 ± 1185 vs
2540 ± 942mm • ms, Po0.05) and for Gubner–Ungerleider
voltage (23.3 ± 1.2 vs 18.2 ± 7.1 mm, Po0.05) were signiﬁcantly
lower for obesity subjects compared with non-obese subjects.
Similar, albeit nonsigniﬁcant, trends were demonstrated for
Sokolow–Lyon voltage, Sokolow–Lyon product and Romhilt–Estes
score criteria. This was despite a trend toward higher mean
indexed LVM in obese subjects with LVH compared with
non-obese subjects with LVH (108.3 ± 21.4 vs 102.0 ± 18.1 kgm−2,
P= 0.3047).
Figure 1. A ﬂow chart demonstrating the study exclusion criteria
and ﬁnal sample size (n= 128). *Image artifact from implantable
loop recorder device precluding volumetric assessment from LV
short-axis SSFP cine stack. AVR, aortic valve replacement; DCM,
idiopathic dilated cardiomyopathy (CMR diagnosis); ECG, electro-
cardiogram; HOCM, hypertrophic obstructive cardiomyopathy (clin-
ical and/or CMR diagnosis); LVNC, left ventricular non-compaction
cardiomyopathy (CMR diagnosis); MI, myocardial infarction (deﬁned
as subendocardial late gadolinium enhancement on CMR); Mod AR,
moderate aortic regurgitation.
Table 2. Demographic and CMR parameters for non-obese and obese
subjects
Non-obese
(n=63)
Obese (n= 65) P-value
Demographic data
Age (year) 50.7± 16.7 51.3± 13.6 0.80
Gender (% male) 52 46 0.60
Height (m) 1.70± 0.11 1.70± 0.10 0.89
Weight (kg) 76.8± 13.2 100.2± 14.8 o0.0001
BMI (kgm−2) 26.4± 2.7 34.7± 4.6 o0.0001
BSA (m2) 1.90± 0.22 2.17± 0.20 o0.0001
Ofﬁce SBP (mmHg) 171.9± 30.0 169.6± 30.1 0.66
Ofﬁce DBP (mmHg) 98.1± 16.0 96.9± 14.9 0.66
Heart rate (b.p.m.) 72.1± 16.2 71.9± 12.1 0.91
No. of
antihypertensives
2.6± 1.9 3.1± 1.9 0.13
ACEi/ARB (%) 71.4 76.9 0.55
CCB (%) 49.2 56.9 0.48
β-Blocker (%) 33.3 38.5 0.58
Diuretic (%) 55.5 72.3 0.07
CMR data
LVEF (%) 66.2± 8.3 70.1± 9.3 o0.05
LV mass (g) 142.8± 42.5 177.0± 57.6 o0.0005
Indexed LV mass
(g m−2)
57.3± 13.9 71.4± 20.5 o0.0001
Maximal wall thickness
(mm)
12.4± 2.9 14.1± 2.8 o0.005
Asymmetric wall
thickness (%)
22.2 33.8 0.17
Cardiac output
(l min− 1)
6.8± 1.7 8.2± 2.1 o0.0001
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; BMI, body mass index; BSA, body surface
area; b.p.m., beats per minute; CCB, calcium channel blocker; CMR, cardiac
magnetic resonance; DBP, diastolic blood pressure; LV, left ventricular; LVEF,
left ventricular ejection fraction; SBP, systolic blood pressure.
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Table 3. Diagnostic performance of the various ECG parameters
Prevalence ECG LVH (%) ROC-AUC (95th CI) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) ACC (%)
Sokolow–Lyon voltage 12 0.633 (0.533–0.732) 19 93 60 66 66
Sokolow–Lyon product 9 0.715 (0.621–0.809) 17 96 72 66 67
Cornell voltage 26 0.752 (0.666–0.809) 43 84 61 72 69
Cornell product 35 0.718 (0.625–0.839) 53 75 56 73 67
Gubner–Ungerleider voltage 32 0.684 (0.584–0.785) 51 79 59 74 69
Romhilt–Estes score 4p 38 — 55 71 53 73 66
Romhilt–Estes score 5p 16 — 28 90 62 68 67
Abbreviations: ACC, accuracy; BSA, body surface area; CI, conﬁdence interval; ECG, electrocardiograph; LVM, LV mass; NPV, negative predictive values;
4p, 4-point; 5p, 5-point; PPV, positive predictive value; ROC-AUC, receiver operator curve-area under curve.
Table 4. Diagnostic performance of the various ECG parameters by obesity
ROC-AUC (95% CI) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) ACC (%)
Sokolow–Lyon voltage
Non-obese 0.611 (0.463–0.759) 17 89* 38* 73* 68
Obese 0.677 (0.545–0.809) 21 97 86 60 63
Sokolow–Lyon product
Non-obese 0.721 (0.575–0.866) 17 93 50* 74* 71
Obese 0.745 (0.623–0.867) 17 100 100 60 63
Cornell voltage
Non-obese 0.796 (0.661–0.930) 56* 87 63 83* 78*
Obese 0.714 (0.590–0.837) 34 81 59 60 60
Cornell product
Non-obese 0796 (0.666–0.927) 61* 83* 55 84* 75*
Obese 0.650 (0.515–0.785) 48 69 56 63 60
Gubner–Ungerleider voltage
Non-obese 0.767 (0.613–0.921) 67* 82* 60 86* 78*
Obese 0.607 (0.467–0.747) 41 61 57 61 60
Romhilt–Estes score 4p
Non-obese — 72* 64* 45* 85* 67
Obese — 45 81 65 64 65
Romhilt–Estes score 5p
Non-obese — 28 89 50* 75* 71
Obese — 29 92 72 61 63
Abbreviations: ACC, accuracy; CI, conﬁdence interval; ECG, electrocardiograph; LVM, LV mass; NPV, negative predictive values; 4p, 4-point; 5p, 5-point; PPV,
positive predictive value; ROC-AUC, receiver operator curve-area under curve. *Po0.05, non-obese value vs obese value for the corresponding ECG criterion.
Table 5. Mean values for different ECG criteria for LVH relative to LVH deﬁned by CMR, with obesity subgroup analysis
ECG criteria LVH on CMR (n=47) No LVH on CMR (n= 81)
Non-obese (n= 18) Obese (n= 29) Non-obese (n= 45) Obese (n= 36)
Sokolow–Lyon voltage (mm) 27.2± 6.2 26.7± 9.2 24.2± 8.2 21.4± 6.5
Sokolow–Lyon Product (mm ⋅ms) 2785± 737 2679± 921 2239± 770 1918± 722
Cornell voltage (mm) 26.4± 9.4* 22.1± 5.7* 16.7± 5.7 17.3± 6.0
Cornell product (mm ⋅ms) 3023± 1185§ 2540± 942§ 1982± 651 2072± 563
Gubner–Ungerleider voltage (mm) 23.3± 1.2^ 18.2± 7.1^ 14.5± 6.9 15.7± 6.4
Romhilt–Estes score 3.9± 2.5 3.3± 2.9 2.3± 2.5 1.5± 1.9
Abbreviations: ACC, accuracy; CI, conﬁdence interval; CMR, cardiac magnetic resonance; ECG, electrocardiograph; LV H, left ventricular hypertrophy. *Po0.05,
Cornell voltage: LVH non-obese vs LVH obese. §Po0.05, Cornell product: LVH non-obese vs LVH obese. ^Po0.05, Gubner–Ungerleider voltage: LVH non-obese
vs LVH obese.
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However, in the absence of LVH by CMR, there was no
signiﬁcant difference between the mean ECG criteria values for
subjects with obesity and subjects without obesity (Table 5). In
fact, there were nonsigniﬁcant trends toward higher mean ECG
criteria values in obese individuals without CMR evidence of LVH.
Interestingly, the prevalence of LV remodeling (normal indexed
LVM but increased M/V) was signiﬁcantly higher in those with
obesity compared with non-obese subjects (36% vs 16%, Po0.05)
and consequently the prevalence of structurally normal left
ventricles was signiﬁcantly lower (64% vs 84%, Po0.05).
There was a signiﬁcantly higher mean value for the Cornell
voltage for subjects with remodeling compared with those with
a structurally normal LV (19.8 ± 5.1 vs 16.0 ± 5.8 mm, Po0.05), in
the absence of a signiﬁcant gender difference between the
cohorts. Similar, but nonsigniﬁcant, trends were observed for
Cornell product (2129 ± 51.4 vs 1987 ± 64mm • ms, P= 0.3717) and
Gubner–Ungerleider voltage (16.6 ± 5.4 vs 14.5 ± 7.0 mm,
P= 0.2235) criteria. These trends corresponded to a signiﬁcantly
increased mean indexed LVM, but still within the normal range, for
subjects with remodeling compared with subjects with normal LV
structure (78.9 ± 9.1 vs 69.6 ± 8.7 kg m−2, Po0.0001).
Obesity-speciﬁc partition values
To facilitate comparison of sensitivities, the ECG criteria sensitiv-
ities were calculated relative to a ﬁxed 95% speciﬁcity, as
described previously.10,11,18,26 The obesity-speciﬁc partition values
derived from our cohort are demonstrated in Table 6. At a ﬁxed
95% speciﬁcity, the Cornell voltage had the highest sensitivity
(56%) among non-obese subjects. The recalculated sensitivities
were similar for all criteria in the presence of obesity, but the
highest was achieved with the Sokolow–Lyon product (24%).
Obesity-speciﬁc partition values are presented in Table 6.
DISCUSSION
This is the ﬁrst study to investigate the impact of obesity on the
diagnostic performance of the ECG at detecting LVH relative
to CMR gold-standard using SSFP sequences in a clinical
hypertensive cohort.
We have demonstrated that, in hypertensive subjects with ECG
evidence of LVH, indexed LVM is signiﬁcantly elevated compared
with subjects without ECG evidence for LVH. However, all of the
ECG criteria were poor at excluding LVH as deﬁned by CMR.
Furthermore, the ability of the ECG to exclude LVH deteriorates in
the presence of obesity.
Previous echocardiographic studies have demonstrated the
impact of obesity on the diagnostic performance of the ECG
criteria for echocardiographic deﬁned LVH. Our results demon-
strate that sensitivities of praecordial lead ECG voltage criteria for
the detection of LVH were reduced in the presence of obesity,
which is consistent with a number of such previous studies.21–33
We show that obese subjects with CMR-proven LVH have
signiﬁcantly lower mean values for Cornell voltage, Cornell
product and Gubner–Ugerleider voltage compared with non-
obese subjects. There were similar, albeit nonsigniﬁcant, trends
toward lower values for the other ECG criteria investigated. On the
one hand, previous echocardiographic studies have found no
signiﬁcant differences for the Cornell voltage,23,34 on the other
hand, one study showed an obesity-related increase in the mean
values for Cornell voltage and Cornell product.35 In this latter
study by Okin et al.,35 the increase has been explained by obesity-
associated increase in LVM, and in our cohort, we demonstrated a
nonsigniﬁcant trend toward higher mean indexed LVM in obese
subjects with LVH compared with non-obese subjects with LVH,
and despite this, the ECG criteria values were still attenuated.
Nevertheless, there is consensus between our results and those of
Okin et al.35 that the Cornell product provides a high sensitivity for
obese subjects using traditional partition values.
The inferior sensitivity of the ECG at detecting LVH in the
presence of obesity has previously been explained by the
increased distance of the ECG electrodes from the heart, which
may reduce QRS amplitudes.21 Our results provide further insight
into the mechanism. If the impact of obesity on the ECG criteria
values were simply an insulating phenomenon related to
increased subcutaneous adipose tissue, similar trends toward
lower ECG criteria values should also be observed in obese
individuals without LVH compared with non-obese individuals
without LVH. We found no signiﬁcant difference between these
cohorts. It is important to realize that the absence of LVH does not
equate to a normal ventricular structure. In those without CMR
evidence of LVH, signiﬁcantly more subjects with obesity had LV
remodeling, as deﬁned as no LVH but an abnormally elevated
mass:volume ratio suggesting reduction in LV cavity size,
compared with non-obese subjects. An equilibrium between
increased LVM associated with obesity and the increased electrical
insulation of additional adipose tissue likely determines whether
the ECG criteria values demonstrate any signiﬁcant change in
obese vs non-obese individuals. In those with LVH in our cohort,
the insulating properties would appear to counteract the trend
toward increased indexed LVM in the obese vs non-obese
subjects. Our results suggest that obesity-related increases in
mass:volume ratio result in increased ECG LVH criteria values in
subjects without LVH. The impact of LV remodeling appears to
offset any expected additional electrical insulation properties in
the obese individuals without LVH in our cohort. This may account
for the reduction in speciﬁcity of the ECG at detecting LVH in
obesity. However, the reasons how and why an increase in LVM or
M:V dominates over increased electrical insulation in certain obese
individuals remains uncertain.
Our ﬁndings of signiﬁcantly reduced ECG sensitivity and
speciﬁcity at detecting LVH in the presence of obesity suggest
that a normal ECG in an obese hypertensive patient has a higher
chance of being both falsely reassuring for the absence of LVH
and falsely positive in obese compared with non-obese subjects.
Failing to identify or exclude LVH may alter an individual’s
cardiovascular risk estimate and therefore may have treatment
implications.7 Our obesity-speciﬁc partition values may help to
readdress this issue. At a ﬁxed 95% speciﬁcity, sensitivity was
inferior for obese subjects compared with non-obese subjects for
all criteria except Sokolow–Lyon voltage and Sokolow–Lyon
product. Sensitivity and speciﬁcity need to be interpreted in the
Table 6. Sensitivities and the non-obesity/obesity partition values at 95% speciﬁcity
Combined sensitivity
(%)
Non-obese sensitivity
(%)
Obese sensitivity
(%)
Non-obese partition value Obese partition value
Sokolow–Lyon voltage 11 6 21 ⩾ 38.0 mm ⩾ 33.0 mm
Sokolow–Lyon product 19 17 24 ⩾ 3555mm ⋅ms ⩾ 3275mm ⋅ms
Cornell voltage 32 56 21 ⩾ 25.5 mm ⩾ 27.0 mm
Cornell product 21 33 17 ⩾ 3085mm ⋅ms ⩾ 3035mm ⋅ms
Gubner–Ungerleider
voltage
19 39 17 ⩾ 24.5 mm ⩾25.5 mm
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context of the disease prevalence and these results are likely
related to the relatively low prevalence of ECG LVH with the
Sokolow–Lyon voltage and product criteria (Table 2). The lower
prevalence of ECG LVH with these criteria is consistent with
previous work from Okin et al.35 The best sensitivity for non-obese
subjects (56%) was achieved with the Cornell voltage criterion,
which is consistent with a previous study by Molloy et al.,26 who
demonstrated a sensitivity of 50% for the Cornell product criterion
for antemortem ECG compared with LVM measured by dry weight
at autopsy.26 The optimal sensitivity for obese subjects was
achieved with the Sokolow–Lyon product, using an amended
partition value of ⩾ 3275mm •ms compared with the conven-
tional ⩾ 3710mVms− 1.
Limitations
It is important to realize that direct comparison between our study
and existing echocardiography studies is subject to discrepancy as
our analysis accounted for the inﬂuences of age as well as gender on
LVM by varying the deﬁnition of LVH in relation to these variables in
accordance with established normal ranges.29 Gender-speciﬁc
deﬁnitions of LVH only were used in the previous echocardiographic
studies.8–10 Furthermore, blood pool thresh-holding software
enabled inclusion of papillary muscles and LV trabeculation in the
estimation of LVM to yield as close a noninvasive estimate of dry LV
weight as possible in our study. Consequently, the thresholds and
accuracy for deﬁning LVH will be different between studies, and, as a
result, the proportion of individuals classiﬁed as having LVH will also
differ. Furthermore, differing allometric scaling of LVM between
studies will alter the deﬁnition of LVH and impact on the diagnostic
performance of the ECG.24
In this clinical cohort study, most patients were receiving
antihypertensive medications. Patients with myocardial infarction
and valvular heart disease were excluded. A further study is
therefore required in normotensive individuals and less highly
selected hypertensive patients, for example, untreated hyperten-
sive patients, before the results can be widely extrapolated.
Our study size of 128 patients was modest. However, the ﬁndings
are still likely valid because of the compensation afforded by
the increased accuracy and reproducibility of CMR. For example,
previous work by Myerson et al.36 has demonstrated that the
sample size for CMR can be approximately 6-fold lower than
two-dimensional echocardiography and 12-fold lower than
M-mode echocardiography for a power (1− β error) of 95% to
detect a statistically signiﬁcant change in mean LV mass of 10 g.
Total body fat mass is not routinely measured in our clinical
practice and could not be investigated. BMI was used as a
routinely recorded clinical surrogate. An increase in lean muscle
mass may generate elevated BMI values and the partition values
generated may not be applicable in this context, although a BMI
430 kgm−2 because of increased lean muscle mass is unlikely to
occur, except in very high-performing athletes.
CONCLUSION
ECG evidence of LVH identiﬁes patients with signiﬁcantly elevated
indexed LVM, measured with noninvasive gold-standard SSFP
CMR, for all the ECG criteria investigated.
However, lower sensitivity compared with speciﬁcity was
demonstrated for all the ECG criteria, with further inferior
sensitivities for obese subjects for the majority of ECG criteria
investigated. Obesity attenuates the ECG criteria values in the
presence of LVH. In addition, we have shown that obesity-related
LV remodeling may inﬂuence the diagnostic performance of the
ECG at detecting LVH. The application of obesity-speciﬁc partition
values may help improve the diagnostic performance of the ECG
in this important subgroup of patients with hypertension.
What is known about this topic?
● Detecting LVH in hypertension has prognostic and treatment
implications.
● The ECG can detect LVH and it has been validated against
echocardiographic assessment of LVM.
● There are conﬂicting results of the impact of obesity on the
diagnostic performance of the ECG at detecting LVH.
What this study adds?
● We recalibrate six commonly used the ECG criteria for the diagnosis
of LVH against gold-standard SSFP CMR.
● We show obesity reduces ECG sensitivity by attenuating ECG criteria
values.
● We show obesity reduces ECG speciﬁcity by changes due to LV
remodeling, despite normal LVM.
● We present obesity-speciﬁc partition values to help improve the
diagnostic performance of the ECG.
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